Polybutylcyanoacrylate nanoparticles and drugs of the platinum family: Last status

被引：26

作者：

Fatemeh D.R.A. ^{[1
]}

Ebrahimi Shahmabadi H. ^{[2
]}

Abedi A. ^{[1
]}

Alavi S.E. ^{[2
]}

Movahedi F. ^{[2
]}

Koohi Moftakhari Esfahani M. ^{[2
]}

Zadeh Mehrizi T. ^{[3
]}

Akbarzadeh A. ^{[2
]}

机构：

[1] Department of Inorganic Chemistry, North Tehran Branch, Islamic Azad University, Tehran

[2] Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran

[3] Department of Immunology, Faculty of Medicine, Shahid Beheshti University of Medical Science, Tehran

来源：

Indian Journal of Clinical Biochemistry | 2014年 / 29卷 / 3期

关键词：

Carboplatinum; Cisplatinum; Drug delivery; Emulsion polymerization; Polybutylcyanoacrylate;

D O I：

10.1007/s12291-013-0364-6

中图分类号：

学科分类号：

摘要：

Cisplatinum and carboplatinum drugs from platinum-containing family are anti-cancer drugs. Using these drugs causes side effects. Targeted and selective prescription decreases side effects of the drugs. This can be achieved using nanotechnology. In this study, cisplatinum and carboplatinum drugs were loaded on polybutylcyanoacrylate nanoparticles using emulsion polymerization method. To determine amount of loaded drug onto nanoparticle, spectrophotometry method was used. Evaluation of cytotoxicity of such nanoparticles was performed on MCF-7 cell line using MTT assay. Loading percentage of cisplatinum and carboplatinum drugs on nanoparticles were estimated 4 and 6 %, respectively. Cytotoxicity survival rate for cisplatinum and nanoparticle containing cisplatinum at the lowest concentration (p < 0.01) (20 μM) were estimated 64 ± 1 and 67 ± 0.5 %, respectively. These values at the highest concentration (p < 0.01) (160 μM) were measured 28 ± 0.7 and 31 ± 0.4 %. Additionally for carboplatinum and nanoparticles containing carboplatinum at the concentration (p < 0.01) (20 μM) amounts were estimated to be 80 ± 0.6 and 84 ± 0.6 %, while at the concentration (p < 0.01) (160 μM) were identified to be 44 ± 0.5 and 51 ± 0.2 %, respectively. Probably, due to low level of loading, cytotoxicity of both drugs at nano particle status was decreased in comparison with their standard form. © 2013 Association of Clinical Biochemists of India.

引用

页码：333 / 338

页数：5

共 36 条

[1] Ho Y.-P., Au-Yeung S.C.F., To K.K.W., Platinum-based anticancer agents: Innovative design strategies and biological perspectives, Medicinal Research Reviews, 23, 5, pp. 633-655, (2003)
[2] Wernyj R.P., Morin P.J., Molecular mechanisms of platinum resistance: Still searching for the Achilles' heel, Drug Resistance Updates, 7, 4-5, pp. 227-232, (2004)
[3] Avichezer D., Schechter B., Arnon R., Functional polymers in drug delivery: Carrier-supported CDDP (cis-platin) complexes of polycarboxylates - Effect on human ovarian carcinoma, Reactive and Functional Polymers, 36, 1, pp. 59-69, (1998)
[4] Gianasi E., Wasil M., Evagorou E.G., Keddle A., Wilson G., Duncan R., HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo, European Journal of Cancer, 35, 6, pp. 994-1002, (1999)
[5] Newman M.S., Colbern G.T., Working P.K., Engbers C., Amantea M.A., Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice, Cancer Chemotherapy and Pharmacology, 43, 1, pp. 1-7, (1999)
[6] Malik N., Evagorou E.G., Duncan R., Dendrimer-platinate: A novel approach to cancer chemotherapy, Anti-Cancer Drugs, 10, 8, pp. 767-776, (1999)
[7] Nishiyama N., Kato Y., Sugiyama Y., Kataoka K., Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system, Pharmaceutical Research, 18, 7, pp. 1035-1041, (2001)
[8] Ferruti P., Ranucci E., Trotta F., Gianasi E., Evagorou E.G., Wasil M., Wilson G., Duncan R., Synthesis, characterisation and antitumour activity of platinum(II) complexes of novel functionalised poly(amido amine)s, Macromolecular Chemistry and Physics, 200, 7, pp. 1644-1654, (1999)
[9] Xu P., Van Kirk E.A., Li S., Murdoch W.J., Ren J., Hussain M.D., Et al., Highly stable core-surface-crosslinked nanoparticles as cisplatinum carriers for cancer chemotherapy, Colloids Surf B Biointerfaces, 48, pp. 50-57, (2006)
[10] Hirai M., Minematsu H., Hiramatsu Y., Kitagawa H., Otani T., Iwashita S., Et al., Novel and simple loading procedure of cisplatinum into liposomes and targeting tumor endothelial cells, Int J Pharm, 391, pp. 274-283, (2010)

← 1 2 3 4 →